Silence Therapeutics (SLN) Accounts Payables (2018 - 2026)

Silence Therapeutics has disclosed Accounts Payables across 9 years of filings, most recently posting $10.4 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $10.4 million, down 44.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (down 44.89% YoY), and the FY2025 annual result was $13.4 million, down 18.56% from the prior year.
• Accounts Payables came in at $10.4 million for Q1 2026 at Silence Therapeutics, down from $13.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $18.8 million in Q1 2025 to a low of $10.4 million in Q1 2026.
• The 5-year median for Accounts Payables is $15.1 million (2023), against an average of $15.1 million.
• Across the five-year window, Accounts Payables rose 6.31% in 2024 and slumped 44.89% in 2026, its largest moves.
• Silence Therapeutics' Accounts Payables stood at $14.8 million in 2022, then climbed by 4.11% to $15.4 million in 2023, then rose by 6.31% to $16.4 million in 2024, then slipped by 18.56% to $13.4 million in 2025, then retreated by 22.38% to $10.4 million in 2026.
• The last three Accounts Payables figures came in at $10.4 million (Q1 2026), $13.4 million (Q4 2025), and $17.0 million (Q3 2025), per Business Quant data.